ELAN
Elanco Animal Health IncorporatedHealthcare · $11.2B market cap
Verdict
We can't put a fair value on ELAN right now. Our value came out at less than a tenth of the share price. When our answer is that far from the market, the method most likely doesn't fit this company, so we don't publish a number.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow ELAN
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
2 of the investors we track hold ELAN. In Q2 2026, 1 trimmed. Who we track
Dodge & Cox Funds
Dodge & Cox Funds · as of Q2 2026
$1.7B
67,397,025 shares
Lee Ainslie
Maverick Capital · as of Q2 2026
$2.4M
98,098 shares
Moves in Q2 2026
Trimmed: Lee Ainslie
Insider activity
Since Sep 4, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
About Elanco Animal Health Incorporated
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works